MAPT and Alzheimer disease: Finally, our multimodal stratification has greater statistical power to detect a clinically meaningful change in tau accumulation vs. cognitive decline (PACC change n = 917 vs. tau accumulation n = 637) over the time frame of a standard AD clinical trial (1–3 years), suggesting tau accumulation is a sensitive outcome measure for clinical trials in the earliest stages of AD.